Global biopharmaceutical giant UCB, Inc. plans to invest $2 billion in Georgia to establish its first U.S. pharmaceutical biologics manufacturing facility. The investment will generate 330 new jobs over the next several years at the Rowen Foundation’s state-of-the-art, 2,000-acre science and learning campus in Gwinnett County.
Belgium-based UCB’s North American headquarters is located in Smyrna and currently supports more than 400 jobs. UCB’s expertise spans neurology and immunology.
“This decision reflects our confidence in UCB’s long-term growth and our deep-rooted commitment to the United States,” said Jean-Christophe Tellier, CEO of UCB. “By investing in Georgia, where our U.S. headquarters have been based for more than three decades, we are strengthening our biologics manufacturing capabilities, supporting our innovation pipeline, and creating high-quality jobs in a state that offers outstanding talent, a strong manufacturing tradition, and an ecosystem designed for sustainable, long-term success. This project is expected to generate approximately $5 billion in total economic impact, reflecting the broader value it will create for the region and its communities.”
UCB’s new manufacturing footprint will be located at Rowen and serve as an anchor tenant for the 2,000-acre planned community in metro Atlanta designed to foster collaboration, knowledge sharing, and innovation. The cutting-edge campus will use a digital-first approach by leveraging AI, robotics, and automation while also prioritizing efficiency in the use of any natural resources…